Page last updated: 2024-08-21

azomycin and Nasopharyngeal Carcinoma

azomycin has been researched along with Nasopharyngeal Carcinoma in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
He, X; Huang, Y; Liu, L; Tian, Y; Xue, C; Zhan, J; Zhang, L; Zhao, Y1
Cao, H; Chen, X; Chen, Y; Fan, J; Fu, S; Lin, S; Ren, P; Su, Z; Sun, X; Wu, J; Yang, B; Yang, L; Zhang, Y; Zhou, J; Zhou, Y; Zou, X1
Cook, GJ; Fong, KW; Goh, V; Tan, T; Wee, J; Yip, C1

Reviews

1 review(s) available for azomycin and Nasopharyngeal Carcinoma

ArticleYear
Clinical significance of hypoxia in nasopharyngeal carcinoma with a focus on existing and novel hypoxia molecular imaging.
    Chinese clinical oncology, 2016, Volume: 5, Issue:2

    Topics: Biomarkers, Tumor; Carcinoma; Cell Hypoxia; Coordination Complexes; Humans; Magnetic Resonance Imaging; Molecular Imaging; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Nitroimidazoles; Organometallic Compounds; Oxygen; Positron-Emission Tomography; Prognosis; Thiosemicarbazones; Tomography, Emission-Computed, Single-Photon

2016

Other Studies

2 other study(ies) available for azomycin and Nasopharyngeal Carcinoma

ArticleYear
Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.
    Cancer communications (London, England), 2018, 05-03, Volume: 38, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Cisplatin; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Treatment Outcome; Xenograft Model Antitumor Assays

2018
Synergistic effect of combination topotecan and chronomodulated radiation therapy on xenografted human nasopharyngeal carcinoma.
    International journal of radiation oncology, biology, physics, 2013, Oct-01, Volume: 87, Issue:2

    Topics: Animals; Carcinoma; Cell Hypoxia; Chronotherapy; Combined Modality Therapy; DNA Damage; DNA Topoisomerases, Type I; Dose-Response Relationship, Radiation; Histones; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Nitroimidazoles; Phosphorylation; Radiation Tolerance; Radiation-Sensitizing Agents; Time Factors; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous

2013